| GLYC:GlycoMimetics Inc | | Charting | News | Options | |||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
10.88% $0.23
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 |
|
| BusinessWire |
|
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023. Cash and cash equivalents as of December 31, 2023, were $41.8 million. |
| Full Story → |
|
| Headline News |
|
| GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 |
| 7:00a ET March 13 '24 BusinessWire |
|
|
| GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference |
| 7:00a ET February 26 '24 BusinessWire |
|
|
| GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) |
| 7:00a ET February 12 '24 BusinessWire |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| April 19 '24. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, April 18 '24. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
52.78% 
